Oct 31, 2021 - Health

Moderna says FDA needs more time to assess risks of vaccine in teens

Yacob Reyes

Photo: Miyer Juana/Long Visual Press/Universal Images Group via Getty Images

Moderna said Sunday that the Food and Drug Administration (FDA) is delaying a decision on approving the emergency use of the company's coronavirus vaccine for children ages 12 to 17.

Driving the news: The FDA informed Moderna that it is evaluating the risk of myocarditis, a condition affecting the wall of the heart, after vaccination, per the release.

Moderna said it will delay filing a request for emergency use authorization for children ages 6 to 11 while the FDA continues to assess the vaccine for children ages 12 to 17.
The FDA may not complete its review before January 2022, Moderna said in a press release.

What they're saying: "The Company is fully committed to working closely with the FDA to support their review and is grateful to the FDA for their diligence," Moderna said in a statement.

"Moderna is committed to conducting its own careful review of new external analyses as they become available."

Add Axios on Google

Moderna says FDA needs more time to assess risks of vaccine in teens

What to read next